SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2025
Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.
Synthesis in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2025. The graph read 7 numbers from its abstract, feeding 1 cell of the map: it supports the treatment in 1. It also reports an association that does not count as treatment evidence, such as difference -1.87 (-2.67 to -1.06) for systolic blood pressure (SBP). Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The results showed that, compared to the control group, the semaglutide group significantly reduced systolic blood pressure (SBP) (mean difference [MD] - 2.90, 95% confidence interval [CI] - 3.70 to - 2.11; P < 0.01) and diastolic blood pressure (DBP) (MD - 0.86, 95% CI - 1.34 to - 0.38; P < 0.01).
The higher dose of semaglutide (2.4 mg) was found to significantly lower SBP (MD - 4.31, 95% CI - 5.18 to - 3.44) and DBP (MD - 1.84, 95% CI - 2.70 to - 0.98), although mild heterogeneity was present.
The higher dose of semaglutide (2.4 mg) was found to significantly lower SBP (MD - 4.31, 95% CI - 5.18 to - 3.44) and DBP (MD - 1.84, 95% CI - 2.70 to - 0.98), although mild heterogeneity was present.
The results showed that, compared to the control group, the semaglutide group significantly reduced systolic blood pressure (SBP) (mean difference [MD] - 2.90, 95% confidence interval [CI] - 3.70 to - 2.11; P < 0.01) and diastolic blood pressure (DBP) (MD - 0.86, 95% CI - 1.34 to - 0.38; P < 0.01).
The results showed that, compared to the control group, the semaglutide group significantly reduced systolic blood pressure (SBP) (mean difference [MD] - 2.90, 95% confidence interval [CI] - 3.70 to - 2.11; P < 0.01) and diastolic blood pressure (DBP) (MD - 0.86, 95% CI - 1.34 to - 0.38; P < 0.01).
Read, but not usablea number the graph found but could not read as for or against
Further subgroup analysis revealed that, compared to diabetic populations, semaglutide had a more significant reduction in SBP (- 1.87, 95% CI - 2.67 to - 1.06, vs - 5.02, 95% CI - 6.10 to - 3.94) and DBP (- 0.43, 95% CI - 0.89 to 0.02, vs - 1.96, 95% CI - 3.12 to - 0.80) in non-diabetic populations.
Further subgroup analysis revealed that, compared to diabetic populations, semaglutide had a more significant reduction in SBP (- 1.87, 95% CI - 2.67 to - 1.06, vs - 5.02, 95% CI - 6.10 to - 3.94) and DBP (- 0.43, 95% CI - 0.89 to 0.02, vs - 1.96, 95% CI - 3.12 to - 0.80) in non-diabetic populations.
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
GLP-1 receptor agonists×blood pressure
SupportsOpen on the map →What to test next →9 readable studies in this cell: 3 favour the treatment, 5 find no difference, 1 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.Endocrine · 2026Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
objectiveThe aim was to systematically evaluate the effect of semaglutide on blood pressure in obese populations using meta-analysis methods.
methodsRandomized controlled trials on the effect of semaglutide on blood pressure regulation published from the inception of the databases to October 2024 were searched for in PubMed, Embase, the Cochrane Library, and Web of Science. Stata software was used for statistical analysis of the outcome measures in all included studies. Egger's test was applied to assess the risk of publication bias.
resultsA total of 22 studies involving 15,347 participants were included in this meta-analysis. The results showed that, compared to the control group, the semaglutide group significantly reduced systolic blood pressure (SBP) (mean difference [MD] - 2.90, 95% confidence interval [CI] - 3.70 to - 2.11; P < 0.01) and diastolic blood pressure (DBP) (MD - 0.86, 95% CI - 1.34 to - 0.38; P < 0.01). Further subgroup analysis revealed that, compared to diabetic populations, semaglutide had a more significant reduction in SBP (- 1.87, 95% CI - 2.67 to - 1.06, vs - 5.02, 95% CI - 6.10 to - 3.94) and DBP (- 0.43, 95% CI - 0.89 to 0.02, vs - 1.96, 95% CI - 3.12 to - 0.80) in non-diabetic populations. The higher dose of semaglutide (2.4 mg) was found to significantly lower SBP (MD - 4.31, 95% CI - 5.18 to - 3.44) and DBP (MD - 1.84, 95% CI - 2.70 to - 0.98), although mild heterogeneity was present. Sensitivity analysis showed that the exclusion of any single study did not significantly affect the final results.
conclusionCurrent evidence suggests that semaglutide can lower SBP and DBP, and increasing the dosage can enhance the blood pressure-lowering effect.
Indexed as
Identifiers
40493329What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.